Kymera Therapeutics, Inc. $KYMR Shares Acquired by Siren L.L.C.

Key Points

• Siren L.L.C. increased its stake in Kymera Therapeutics by 9.1%, owning over 3.24 million shares, making it the company's third-largest holding.
• Analysts have set a consensus price target of $58.76 for Kymera, with several firms issuing upgraded ratings, including Bank of America and Jefferies Financial Group.
• Kymera Therapeutics reported a negative EPS of ($0.95) for the last quarter, missing analyst estimates, and experienced a significant decline in revenue compared to the previous year.

Siren L.L.C. increased its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 9.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,240,313 shares of the company's stock after purchasing an additional 270,580 shares during the quarter. Kymera Therapeutics makes up 5.1% of Siren L.L.C.'s portfolio, making the stock its 3rd largest holding. Siren L.L.C. owned approximately 4.98% of Kymera Therapeutics worth $88,687,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in Kymera Therapeutics by 13.0% in the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after purchasing an additional 689,547 shares during the period. Vanguard Group Inc. lifted its position in Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company's stock worth $143,183,000 after purchasing an additional 344,080 shares during the period. Woodline Partners LP lifted its position in Kymera Therapeutics by 2.3% in the fourth quarter. Woodline Partners LP now owns 537,428 shares of the company's stock worth $21,621,000 after purchasing an additional 12,334 shares during the period. Northern Trust Corp lifted its position in Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock worth $17,614,000 after purchasing an additional 53,658 shares during the period. Finally, Janus Henderson Group PLC raised its stake in Kymera Therapeutics by 2,397.9% during the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company's stock worth $15,197,000 after acquiring an additional 362,276 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on KYMR. Jefferies Financial Group set a $64.00 price objective on Kymera Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 25th. Wells Fargo & Company dropped their price objective on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. HC Wainwright reiterated a "buy" rating and set a $60.00 price objective (up from $54.00) on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Finally, BTIG Research reiterated a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $59.39.

Kymera Therapeutics Stock Up 3.2%

KYMR stock traded up $1.50 during midday trading on Tuesday, reaching $48.78. The stock had a trading volume of 895,131 shares, compared to its average volume of 588,072. The business has a fifty day simple moving average of $43.58 and a two-hundred day simple moving average of $37.53. The firm has a market cap of $3.49 billion, a price-to-earnings ratio of -14.06 and a beta of 2.17. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The company had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. During the same quarter last year, the business posted ($0.58) EPS. Kymera Therapeutics's quarterly revenue was down 55.1% on a year-over-year basis. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the transaction, the chief executive officer owned 660,482 shares of the company's stock, valued at $32,363,618. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Bros. Advisors Lp Baker bought 655,500 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The shares were acquired at an average cost of $44.00 per share, for a total transaction of $28,842,000.00. Following the completion of the acquisition, the director directly owned 6,117,295 shares in the company, valued at $269,160,980. The trade was a 12.00% increase in their position. The disclosure for this purchase can be found here. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.